FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:SGCD-RARA

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: SGCD-RARA
FusionPDB ID: 81252
FusionGDB2.0 ID: 81252
HgeneTgene
Gene symbol

SGCD

RARA

Gene ID

6444

5914

Gene namesarcoglycan deltaretinoic acid receptor alpha
Synonyms35DAG|CMD1L|DAGD|LGMDR6|SG-delta|SGCDP|SGDNR1B1|RAR
Cytomap

5q33.2-q33.3

17q21.2

Type of geneprotein-codingprotein-coding
Descriptiondelta-sarcoglycan35 kDa dystrophin-associated glycoproteindelta-SGdystrophin associated glycoprotein, delta sarcoglycanplacental delta sarcoglycansarcoglycan, delta (35kDa dystrophin-associated glycoprotein)retinoic acid receptor alphaRAR-alphanuclear receptor subfamily 1 group B member 1nucleophosmin-retinoic acid receptor alpha fusion protein NPM-RAR long formretinoic acid nuclear receptor alpha variant 1retinoic acid nuclear receptor alpha variant 2
Modification date2020032820200327
UniProtAcc.

P10276

Main function of 5'-partner protein: FUNCTION: Receptor for retinoic acid (PubMed:19850744, PubMed:16417524, PubMed:20215566). Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes (PubMed:28167758). The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5 (PubMed:28167758, PubMed:19398580). In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone deacetylation, chromatin condensation and transcriptional suppression (PubMed:16417524). On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation (PubMed:9267036, PubMed:19850744, PubMed:20215566). Formation of a complex with histone deacetylases might lead to inhibition of RARE DNA element binding and to transcriptional repression (PubMed:28167758). Transcriptional activation and RARE DNA element binding might be supported by the transcription factor KLF2 (PubMed:28167758). RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis (By similarity). Has a role in the survival of early spermatocytes at the beginning prophase of meiosis (By similarity). In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes (By similarity). In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). Together with RXRA, positively regulates microRNA-10a expression, thereby inhibiting the GATA6/VCAM1 signaling response to pulsatile shear stress in vascular endothelial cells (PubMed:28167758). In association with HDAC3, HDAC5 and HDAC7 corepressors, plays a role in the repression of microRNA-10a and thereby promotes the inflammatory response (PubMed:28167758). {ECO:0000250|UniProtKB:P11416, ECO:0000269|PubMed:16417524, ECO:0000269|PubMed:19398580, ECO:0000269|PubMed:19850744, ECO:0000269|PubMed:20215566, ECO:0000269|PubMed:28167758, ECO:0000269|PubMed:9267036}.
Ensembl transtripts involved in fusion geneENST idsENST00000337851, ENST00000435422, 
ENST00000447401, ENST00000517913, 
ENST00000394081, ENST00000394086, 
ENST00000420042, ENST00000425707, 
ENST00000254066, ENST00000394089, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score12 X 10 X 6=72029 X 39 X 17=19227
# samples 1355
** MAII scorelog2(13/720*10)=-2.46948528330122
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(55/19227*10)=-5.12755824682814
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: SGCD [Title/Abstract] AND RARA [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: SGCD [Title/Abstract] AND RARA [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)SGCD(156022061)-RARA(38504568), # samples:2
Anticipated loss of major functional domain due to fusion event.SGCD-RARA seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
SGCD-RARA seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
SGCD-RARA seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
SGCD-RARA seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneRARA

GO:0007165

signal transduction

2825025

TgeneRARA

GO:0030853

negative regulation of granulocyte differentiation

19917671

TgeneRARA

GO:0032689

negative regulation of interferon-gamma production

18416830

TgeneRARA

GO:0032720

negative regulation of tumor necrosis factor production

18416830

TgeneRARA

GO:0032736

positive regulation of interleukin-13 production

18416830

TgeneRARA

GO:0032753

positive regulation of interleukin-4 production

18416830

TgeneRARA

GO:0032754

positive regulation of interleukin-5 production

18416830

TgeneRARA

GO:0045630

positive regulation of T-helper 2 cell differentiation

18416830

TgeneRARA

GO:0045892

negative regulation of transcription, DNA-templated

20080953

TgeneRARA

GO:0045893

positive regulation of transcription, DNA-templated

18845237|19850744|20080953

TgeneRARA

GO:0045944

positive regulation of transcription by RNA polymerase II

19850744|21131358

TgeneRARA

GO:0071300

cellular response to retinoic acid

19917671

TgeneRARA

GO:0071391

cellular response to estrogen stimulus

20080953



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:156022061/chr17:38504568)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across SGCD (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across RARA (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000517913SGCDchr5156022061+ENST00000254066RARAchr1738504568+26458643622074570
ENST00000517913SGCDchr5156022061+ENST00000394089RARAchr1738504568+21808643622074570
ENST00000435422SGCDchr5156022061+ENST00000254066RARAchr1738504568+27679863522196614
ENST00000435422SGCDchr5156022061+ENST00000394089RARAchr1738504568+23029863522196614
ENST00000447401SGCDchr5156022061+ENST00000254066RARAchr1738504568+280210215192231570
ENST00000447401SGCDchr5156022061+ENST00000394089RARAchr1738504568+233710215192231570
ENST00000337851SGCDchr5156022061+ENST00000254066RARAchr1738504568+280210215192231570
ENST00000337851SGCDchr5156022061+ENST00000394089RARAchr1738504568+233710215192231570

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000517913ENST00000254066SGCDchr5156022061+RARAchr1738504568+0.0145864840.98541343
ENST00000517913ENST00000394089SGCDchr5156022061+RARAchr1738504568+0.018021130.98197895
ENST00000435422ENST00000254066SGCDchr5156022061+RARAchr1738504568+0.013303950.9866961
ENST00000435422ENST00000394089SGCDchr5156022061+RARAchr1738504568+0.0175981410.9824019
ENST00000447401ENST00000254066SGCDchr5156022061+RARAchr1738504568+0.019756930.980243
ENST00000447401ENST00000394089SGCDchr5156022061+RARAchr1738504568+0.0249306190.9750694
ENST00000337851ENST00000254066SGCDchr5156022061+RARAchr1738504568+0.019756930.980243
ENST00000337851ENST00000394089SGCDchr5156022061+RARAchr1738504568+0.0249306190.9750694

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for SGCD-RARA

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
SGCDchr5156022061RARAchr17385045681021166NNEVVVGAERLRVLAIETQSSSSEEI
SGCDchr5156022061RARAchr1738504568864166NNEVVVGAERLRVLAIETQSSSSEEI
SGCDchr5156022061RARAchr1738504568986210NNEVVVGAERLRVLAIETQSSSSEEI

Top

Potential FusionNeoAntigen Information of SGCD-RARA in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
SGCD-RARA_156022061_38504568.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
SGCD-RARAchr5156022061chr17385045681021HLA-B14:02ERLRVLAI0.99980.806816
SGCD-RARAchr5156022061chr17385045681021HLA-B14:01ERLRVLAI0.99980.806816
SGCD-RARAchr5156022061chr17385045681021HLA-B50:02AERLRVLAI0.98040.5934716
SGCD-RARAchr5156022061chr17385045681021HLA-B45:01AERLRVLAI0.97830.766716
SGCD-RARAchr5156022061chr17385045681021HLA-B08:09AERLRVLAI0.96350.5969716
SGCD-RARAchr5156022061chr17385045681021HLA-B41:01AERLRVLAI0.78610.7851716
SGCD-RARAchr5156022061chr17385045681021HLA-B50:01AERLRVLAI0.19560.7848716
SGCD-RARAchr5156022061chr17385045681021HLA-B52:01AERLRVLAI0.06490.9067716
SGCD-RARAchr5156022061chr17385045681021HLA-B39:12ERLRVLAI0.99880.8551816
SGCD-RARAchr5156022061chr17385045681021HLA-B14:03ERLRVLAI0.97760.8549816
SGCD-RARAchr5156022061chr17385045681021HLA-B40:06AERLRVLAI0.9990.7679716
SGCD-RARAchr5156022061chr17385045681021HLA-B41:03AERLRVLAI0.78530.5527716
SGCD-RARAchr5156022061chr17385045681021HLA-B50:04AERLRVLAI0.19560.7848716
SGCD-RARAchr5156022061chr17385045681021HLA-B50:05AERLRVLAI0.19560.7848716

Top

Potential FusionNeoAntigen Information of SGCD-RARA in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
SGCD-RARA_156022061_38504568.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
SGCD-RARAchr5156022061chr17385045681021DRB1-0403RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0413RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0413ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0415RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0415ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0427RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0427ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0436RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0436ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0437RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0439RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0440RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0440ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0441RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0442RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0442ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0444RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0444ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0446RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0449RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0450RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0450ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0451RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0451ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0452RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0453RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0453ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0455RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0455ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0456RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0456ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0458RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0458ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0459RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0460RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0465RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0468RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0468ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0470RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0470ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0471RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0473RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0478RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0479RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0479ERLRVLAIETQSSSS823
SGCD-RARAchr5156022061chr17385045681021DRB1-0485RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-0488RLRVLAIETQSSSSE924
SGCD-RARAchr5156022061chr17385045681021DRB1-1113NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1113NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1117NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1117NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1152NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1152NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1189NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1189NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1343NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1354NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1354NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1376NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1377NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1401NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1401NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1404NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1404NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1405NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1405NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1406NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1407NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1407NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1408NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1408NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1411NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1411NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1414NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1414NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1416NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1416NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1418NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1418NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1418EVVVGAERLRVLAIE217
SGCD-RARAchr5156022061chr17385045681021DRB1-1420NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1423NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1423NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1426NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1426NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1428NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1428NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1429NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1431NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1431NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1432NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1432NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1433NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1433NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1434NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1434NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1435NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1435NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1436NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1436NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1437NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1438NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1438NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1439NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1439NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1442NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1442NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1443NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1443NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1444NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1444NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1445NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1445NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1450NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1450NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1454NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1454NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1455NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1455NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1456NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1456NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1458NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1458NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1459NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1459NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1460NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1460NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1461NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1461NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1462NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1462NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1464NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1464NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1465NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1465NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1468NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1470NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1470NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1471NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1471NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1472NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1472NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1473NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1475NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1475NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1481NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1481NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1482NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1482NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1483NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1486NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1486NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1487NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1487NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1488NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1488NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1490NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1490NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1491NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1491NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1495NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1495NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1496NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1496NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1497NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1497NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB1-1499NNEVVVGAERLRVLA015
SGCD-RARAchr5156022061chr17385045681021DRB1-1499NEVVVGAERLRVLAI116
SGCD-RARAchr5156022061chr17385045681021DRB4-0101AERLRVLAIETQSSS722
SGCD-RARAchr5156022061chr17385045681021DRB4-0103AERLRVLAIETQSSS722
SGCD-RARAchr5156022061chr17385045681021DRB4-0104AERLRVLAIETQSSS722
SGCD-RARAchr5156022061chr17385045681021DRB4-0106AERLRVLAIETQSSS722
SGCD-RARAchr5156022061chr17385045681021DRB4-0107AERLRVLAIETQSSS722
SGCD-RARAchr5156022061chr17385045681021DRB4-0108AERLRVLAIETQSSS722

Top

Fusion breakpoint peptide structures of SGCD-RARA

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
2641GAERLRVLAIETQSSGCDRARAchr5156022061chr17385045681021

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of SGCD-RARA

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN2641GAERLRVLAIETQS-7.15543-7.26883
HLA-B14:023BVN2641GAERLRVLAIETQS-4.77435-5.80965
HLA-B52:013W392641GAERLRVLAIETQS-6.80875-6.92215
HLA-B52:013W392641GAERLRVLAIETQS-4.20386-5.23916
HLA-A11:014UQ22641GAERLRVLAIETQS-7.5194-8.5547
HLA-A11:014UQ22641GAERLRVLAIETQS-6.9601-7.0735
HLA-A24:025HGA2641GAERLRVLAIETQS-7.52403-7.63743
HLA-A24:025HGA2641GAERLRVLAIETQS-5.82433-6.85963
HLA-B27:056PYJ2641GAERLRVLAIETQS-3.28285-4.31815
HLA-B44:053DX82641GAERLRVLAIETQS-5.91172-6.94702
HLA-B44:053DX82641GAERLRVLAIETQS-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of SGCD-RARA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
SGCD-RARAchr5156022061chr1738504568716AERLRVLAIAAAGATTACGAGTTTTAGCCATTGAGA
SGCD-RARAchr5156022061chr1738504568816ERLRVLAIGATTACGAGTTTTAGCCATTGAGA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
SGCD-RARAchr5156022061chr1738504568015NNEVVVGAERLRVLAATGAAGTGGTAGTAGGAGCTGAAAGATTACGAGTTTTAGCCATTG
SGCD-RARAchr5156022061chr1738504568116NEVVVGAERLRVLAIAAGTGGTAGTAGGAGCTGAAAGATTACGAGTTTTAGCCATTGAGA
SGCD-RARAchr5156022061chr1738504568217EVVVGAERLRVLAIETGGTAGTAGGAGCTGAAAGATTACGAGTTTTAGCCATTGAGACCC
SGCD-RARAchr5156022061chr1738504568722AERLRVLAIETQSSSAAAGATTACGAGTTTTAGCCATTGAGACCCAGAGCAGCAGTTCTG
SGCD-RARAchr5156022061chr1738504568823ERLRVLAIETQSSSSGATTACGAGTTTTAGCCATTGAGACCCAGAGCAGCAGTTCTGAAG
SGCD-RARAchr5156022061chr1738504568924RLRVLAIETQSSSSETACGAGTTTTAGCCATTGAGACCCAGAGCAGCAGTTCTGAAGAGA

Top

Information of the samples that have these potential fusion neoantigens of SGCD-RARA

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCASGCD-RARAchr5156022061ENST00000337851chr1738504568ENST00000254066TCGA-BH-A1EV-01A

Top

Potential target of CAR-T therapy development for SGCD-RARA

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneSGCDchr5:156022061chr17:38504568ENST00000337851+6936_56167291.0TransmembraneHelical%3B Signal-anchor for type II membrane protein
HgeneSGCDchr5:156022061chr17:38504568ENST00000435422+5836_56166290.0TransmembraneHelical%3B Signal-anchor for type II membrane protein
HgeneSGCDchr5:156022061chr17:38504568ENST00000447401+6836_56167257.0TransmembraneHelical%3B Signal-anchor for type II membrane protein
HgeneSGCDchr5:156022061chr17:38504568ENST00000517913+81036_56167257.0TransmembraneHelical%3B Signal-anchor for type II membrane protein

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to SGCD-RARA

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to SGCD-RARA

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
TgeneRARAC0023487Acute Promyelocytic Leukemia24CTD_human;ORPHANET
TgeneRARAC0036341Schizophrenia3PSYGENET
TgeneRARAC0006142Malignant neoplasm of breast1CTD_human
TgeneRARAC0009363Congenital ocular coloboma (disorder)1GENOMICS_ENGLAND
TgeneRARAC0010701Phyllodes Tumor1CTD_human
TgeneRARAC0085183Neoplasms, Second Primary1CTD_human
TgeneRARAC0086696Neoplasms, Therapy-Associated1CTD_human
TgeneRARAC0149940Sciatic Neuropathy1CTD_human
TgeneRARAC0154748Lesion of Sciatic Nerve1CTD_human
TgeneRARAC0206650Fibroadenoma1CTD_human
TgeneRARAC0242013Sciatic Neuritis1CTD_human
TgeneRARAC0525045Mood Disorders1PSYGENET
TgeneRARAC0600066Malignant Cystosarcoma Phyllodes1CTD_human
TgeneRARAC0678222Breast Carcinoma1CTD_human
TgeneRARAC0751924Neuralgia-Neuritis, Sciatic Nerve1CTD_human
TgeneRARAC0751925Sciatic Nerve Palsy1CTD_human
TgeneRARAC0877578Treatment related secondary malignancy1CTD_human
TgeneRARAC1257931Mammary Neoplasms, Human1CTD_human
TgeneRARAC1458155Mammary Neoplasms1CTD_human
TgeneRARAC2239176Liver carcinoma1CTD_human
TgeneRARAC4704874Mammary Carcinoma, Human1CTD_human